Skip to main content
Figure 1 | Vascular Cell

Figure 1

From: Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor

Figure 1

The addition of SC236 to bevacizumab significantly reduces the incidence of metastasis as compared to VEGF inhibition alone. (A) As compared to controls, SC236 treatment reduced tumor weight by 39% (P = 0.042), whereas BV-treated tumors were reduced by 76% (P = 0.0002). The addition of SC236 to BV treatment did not further decrease primary tumor weight (74% reduction from controls, P = NS as compared to BV alone). Tumor weights are expressed as percentage of control tumors, and Kruskal-Wallis analysis used to determine significance. (B) The incidence of metastasis was determined by examining 3 levels from the right lung. 12/13 or 92% of control animals had detectable metastases, whereas 11/17 (65%) of SC236 treated animals had lung deposits (P = NS). The incidence of metastasis in BV-treated animals was significantly reduced as compared to controls (8/17 animals, 47%, P = 0.011). Combining SC236 with BV treatment further significantly reduced metastasis (2/15 animals, 13%, P = 0.0001 as compared to controls and P = 0.046 as compared to BV treatment alone).

Back to article page

Vascular Cell

ISSN: 2045-824X

Contact us